Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2007 1
2008 3
2009 2
2010 3
2011 4
2012 3
2013 2
2014 1
2015 2
2016 2
2017 1
2018 2
2019 4
2020 8
2021 9
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Phenotypes of MASLD-associated hepatocellular carcinoma.
Rivera-Esteban J, Muñoz-Martínez S, Higuera M, Sena E, Bermúdez-Ramos M, Bañares J, Martínez-Gomez M, Cusidó MS, Jiménez-Masip A, Francque SM, Tacke F, Minguez B, Pericàs JM. Rivera-Esteban J, et al. Among authors: minguez b. Clin Gastroenterol Hepatol. 2024 Apr 9:S1542-3565(24)00310-0. doi: 10.1016/j.cgh.2024.03.028. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38604295 Review.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q, Klein C, Caruso S, Maille P, Allende DS, Mínguez B, Iavarone M, Ningarhari M, Casadei-Gardini A, Pedica F, Rimini M, Perbellini R, Boulagnon-Rombi C, Heurgué A, Maggioni M, Rela M, Vij M, Baulande S, Legoix P, Lameiras S; HCC-AI study group; Bruges L, Gnemmi V, Nault JC, Campani C, Rhee H, Park YN, Iñarrairaegui M, Garcia-Porrero G, Argemi J, Sangro B, D'Alessio A, Scheiner B, Pinato DJ, Pinter M, Paradis V, Beaufrère A, Peter S, Rimassa L, Di Tommaso L, Vogel A, Michalak S, Boursier J, Loménie N, Ziol M, Calderaro J. Zeng Q, et al. Among authors: minguez b. Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0. Epub 2023 Nov 8. Lancet Oncol. 2023. PMID: 37951222
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma.
Pinato DJ, Kaneko T, D'Alessio A, Forner A, Fessas P, Minguez B, Giannini EG, Grillo F, Díaz A, Mauri FA, Fulgenzi CAM, Dalla Pria A, Goldin RD, Pieri G, Toniutto P, Avellini C, Plaz Torres MC, Akarca AU, Marafioti T, Bhoori S, Miró JM, Bower M, Bräu N, Mazzaferro V. Pinato DJ, et al. Among authors: minguez b. JHEP Rep. 2023 Mar 22;5(7):100741. doi: 10.1016/j.jhepr.2023.100741. eCollection 2023 Jul. JHEP Rep. 2023. PMID: 37274775 Free PMC article.
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Miho M, Radu P, Dufour JF, Verslype C, Zimpel C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Bejjani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, Llovet JM. Haber PK, et al. Among authors: minguez b. Gastroenterology. 2023 Jan;164(1):72-88.e18. doi: 10.1053/j.gastro.2022.09.005. Epub 2022 Sep 12. Gastroenterology. 2023. PMID: 36108710 Free article.
Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management.
Higuera M, Vargas-Accarino E, Torrens M, Gregori J, Salcedo MT, Martínez-Campreciós J, Torres G, Bermúdez-Ramos M, Bilbao I, Guerrero-Murillo M, Serres-Créixams X, Merino X, Rodríguez-Frías F, Quer J, Mínguez B. Higuera M, et al. Among authors: minguez b. Cancers (Basel). 2022 Aug 11;14(16):3875. doi: 10.3390/cancers14163875. Cancers (Basel). 2022. PMID: 36010868 Free PMC article.
Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma.
Soria A, Calvo M, Casas M, Vidales Z, Muñoz-Martínez S, Sapena V, Puigvehi M, Canillas L, Guardeño R, Gallego A, Mínguez B, Horta D, Clos A, Montoliu S, Roget M, Reig M, Vergara M. Soria A, et al. Among authors: minguez b. Front Oncol. 2022 Aug 2;12:829483. doi: 10.3389/fonc.2022.829483. eCollection 2022. Front Oncol. 2022. PMID: 35982971 Free PMC article.
Correction to: Foreword.
Mínguez B, Lledó-Navarro JL. Mínguez B, et al. Clin Drug Investig. 2022 Aug;42(8):703. doi: 10.1007/s40261-022-01174-2. Clin Drug Investig. 2022. PMID: 35788977 Free PMC article. No abstract available.
Correction to: Foreword.
Mínguez B, Lledó-Navarro JL. Mínguez B, et al. Clin Drug Investig. 2022 Jun;42(Suppl 1):3. doi: 10.1007/s40261-022-01167-1. Clin Drug Investig. 2022. PMID: 35616885 Free PMC article. No abstract available.
55 results